NCT02032004Phase 3Completed

Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure

Study sponsor: Mesoblast, Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2020-01-30Actual
Enrollment · participants565Actual
Source updated2026-03-23Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Time to recurrent non-fatal decompensated heart failure major adverse cardiac events (HF-MACE) that occur prior to the first terminal cardiac event (TCE).. After: Measure: Time to Recurrent Non-fatal Decompensated Heart Failure Major Adverse Cardiac Events (HF-MACE) That Occur Prior to the First Terminal Cardiac Event (TCE).

Actual enrollment decreased by 1 participants

Before: 566 participants (actual). After: 565 participants (actual).

Primary completion date changed

Before: 29 May 2020. After: 30 Jan 2020.

Check registry source